// App-Quantinova.ai

BSH2020‐PO‐065 : A review of the use of rasburicase for tumour lysis syndrome at Nottingham University Hospitals NHS Trust

Researchers

Presenter

  • S. A. Kazmi

Principal Investigators

  • F. Wadelin

Medical Centers

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Burkitt lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • RNA-binding protein FUS/TLS

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Allopurinol

  • Rasburicase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved